API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Through the acquisition, the company will utilize Deciphera's pipeline and approved products, which include Qinlock (ripretinib), indicated for treating fourth-line gastrointestinal stromal tumors.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million
Deal Type: Acquisition April 29, 2024
Details:
Under the terms of the agreement, GENESIS Pharma will exclusively commercialize Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2024
Details:
Qinlock (ripretinib), recently approved in Singapore, is an orally administered switch-control kinase inhibitor developed for the treatment of GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2023
Details:
Qinlock (ripretinib) is an orally administered switch-control kinase inhibitor developed for the treatment of gastrointestinal stromal tumor, or GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
QINLOCK (Ripretinib) is an orally administered switch-control kinase inhibitor developed for the treatment of gastrointestinal stromal tumor, or GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
QINLOCK (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
Efficacy observed with QINLOCK (ripretinib) tyrosine kinase inhibitor, was comparable to sunitinib with a more favorable safety and tolerability profile in GIST patients previously treated with Imatinib.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
QINLOCK (ripretinib), is an orally administered switch-control kinase inhibitor engineered using our proprietary drug discovery platform and developed for the treatment of gastrointestinal stromal tumor, or GIST.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
Following a detailed review of its portfolio and growth opportunities, Deciphera will focus its resources on the continued advancement of vimseltinib and DCC-3116, while discontinuing the rebastinib program.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Company announced that the European Commission has approved Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor, who have received prior treatment with three or more kinase inhibitors.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
QINLOCK (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Platinum-Resistant Ovarian Cancer.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK, a switch-control tyrosine kinase inhibitor, compared to sunitinib in patients with GIST previously treated with imatinib.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2020
Details:
Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients in Australia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2020
Details:
The INVICTUS Phase 3 clinical study is a randomized (2:1) study to evaluate the safety, tolerability, and efficacy of QINLOCK compared to placebo in 129 patients with advanced GIST whose previous therapies have included at least imatinib, sunitinib, and regorafenib.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
The publication highlighted results from the Company’s ongoing Phase 1 study of ripretinib in patients with second-line through fourth-line plus GIST.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
China’s NMPA has granted priority review status to the New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: DCC-2618
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Qinlock's approval was based on the results of an international clinical trial that enrolled 129 patients with advanced GIST who had received prior treatment with other FDA-approved targeted therapies, imatinib, sunitinib and regorafenib.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Deciphera intends to use the net proceeds from the offering to fund continued growth of its commercial and medical affairs capabilities.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 19, 2020
Details:
FDA has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib,
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2020